Summary of specific safety evaluations in clinical studies of fingolimod in multiple sclerosis: cardiovascular, ophthalmic, hepatic events and relationship between lymphocyte reduction and infections: O210


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles